Clinical trials: Hepatic Neoplasm
Liver Neoplasms, Hepatocellular Carcinoma
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy
This trial is a single arm, non-randomized prospective trial. The objective of this trial is to evaluate the efficacy and safety of the HistoSonics System for the treatment of primary or metastatic tumors located in the liver.
- Conditions
- Liver Neoplasms, Hepatocellular Carcinoma, Liver Metastases
- Trial name
- #HOPE4LIVER US (NCT04572633)
- Testing
- HistoSonics System
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- HistoSonics, Inc.
Hepatocellular Carcinoma
Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer
The purpose of the study is to evaluate the efficacy and safety of PEG-BCT-100 as the second-line therapy following sorafenib in advanced HCC patients.
- Trial name
- NCT02089763
- Testing
- pegylated recombinant human arginase
- Where
- Hong Kong
- Volunteers
- 27 people
- Sponsor
- Bio-Cancer Treatment International Limited
Advanced Solid Tumors, Hepatocellular Carcinoma
A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
This is an open-label, multicenter, phase 1 dose escalation study of BBI503 monotherapy, or BBI503 in combination with Sorafenib.
- Trial name
- NCT02354898
- Testing
- BBI503, Sorafenib
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Solid Tumours
Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the pharmacokinetics (PK) of AZD9291 in patients with mild or moderate hepatic impairment compared to patients with normal hepatic function…
- Trial name
- NCT02161770
- Testing
- AZD9291 tablet dosing, Pharmacokinetic sampling - AZD9291, Pharmacokinetic sampling - AZ5140 and AZ7550
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
A single-arm, open-label clinical trial, focus on the safety and efficacy of TQB2450 injection combined with Anlotinib hydrochloride capsule in patients with advanced biliary adenocarcinoma/hepatocellular carcinoma
- Trial name
- NCT03825705
- Testing
- TQB2450 injection, Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HCC - Hepatocellular Carcinoma
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
The goal of this clinical trial is to learn if drug AST-3424 works to treat AKR1C3 high expressing advanced hepatocellular carcinoma after failure of systemic therapy with immune checkpoint inhibitors.
- Trial name
- NCT07310173
- Testing
- AST-3424, Regorafenib Tablets
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Hepatocellular Cancer
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world…
- Trial name
- NCT02954094
- Where
- 71 sites in United States, France and 3 more
- Volunteers
- 10,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Metastatic Hepatocellular Carcinoma, Solid Tumors
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic…
- Conditions
- Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification
- Trial name
- SURF431 (NCT06915753)
- Testing
- TYRA-430
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 125 people
- Sponsor
- Tyra Biosciences, Inc
Advanced Liver Cancer
A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
This is a phase Ib/II trial to evaluate the safety, pharmacokinetics and preliminary efficacy of QL1706 or QL1604 combined with bevacizumab in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT05603039
- Testing
- QL1706, QL1604, Bevacizumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Carcinoma, Hepatocellular, Hepatocellular Cancer
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that…
- Conditions
- Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
- Trial name
- NCT07227012
- Testing
- PF-08634404, Ipilimumab
- Where
- 60 sites in United States, China and 3 more
- Volunteers
- 138 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT01210495
- Testing
- Axitinib (AG-013736), Best Supportive Care
- Where
- 77 sites in United States, Belgium and 11 more
- Volunteers
- 224 people
- Sponsor
- Pfizer
Hepatic Impairment, Healthy Volunteers
Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
The purpose of this study is to assess the drug levels and safety of golcadomide (BMS-986369) in adult participants with moderate and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic…
- Trial name
- NCT06535399
- Testing
- BMS-986369
- Where
- 3 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Celgene
Hepatic Impairment, Solid Tumor
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment
This is a multi-center, open-label, Phase 1 study to evaluate the impact of hepatic impairment on the pharmacokinetics of Tivantinib in cancer subjects with varying degrees of hepatic function, from normal to severely impaired.
- Conditions
- Hepatic Impairment, Solid Tumor, Cancer
- Trial name
- NCT02150733
- Testing
- Tivantinib
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Daiichi Sankyo
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer
- Trial name
- NCT05953337
- Testing
- EYE90 Microspheres Treatment
- Where
- 22 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- ABK Biomedical
Primary Hepatocellular Carcinoma
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
The objective of this pilot study is to evaluate the safety, tolerability and activity of the monoclonal antibody CT-011 administered intravenously to patients with Primary Hepatocellular Carcinoma.
- Trial name
- NCT00966251
- Testing
- CT-011
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- CureTech Ltd
Carcinoma, Hepatocellular
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Mapatumumab is a fully human, agonist monoclonal antibody that activates the cell death pathway in tumor cells by specifically binding to TRAIL-R1 with high affinity.
- Trial name
- NCT01258608
- Testing
- Mapatumumab, Sorafenib
- Where
- 43 sites in United States, Germany and 5 more
- Volunteers
- 101 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
This is a Phase I, first-in-human, open-label study of CRPA1A2, a bispecific T-cell engager, in participants with HLA-A*02:01-positive and MAGE-A1-positive advanced solid tumors.
- Conditions
- Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07583316
- Testing
- CRPA1A2
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Breast Cancer, Glioma
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast…
- Conditions
- Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00909558
- Testing
- Autologous Natural Killer / Natural Killer T Cell Immunotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Envita Medical Center, Inc.
Ovarian Cancer, Bladder Cancer
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as…
- Conditions
- Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04580485
- Testing
- INCB106385, INCMGA00012
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 54 people
- Sponsor
- Incyte Corporation